In Depth 22 Nov 2024 Can AlphaFold3’s open-source platform revolutionize the way we discover drugs? Find out how Google DeepMind’s AlphaFold3 platform could help scientists revolutionize the field of drug discovery. November 22, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 22 Nov 2024Could antigen modulation address autoimmune diseases? To tell us more about antigen modulation this week is Pete Joyce, CEO and co-founder of Grey Wolf Therapeutics. November 22, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 21 Nov 2024 Huntington’s disease: a therapeutic field on a bumpy ride For years, biotechs have been trying to develop medicines to cure the disease but much to no avail. Now, as clinical studies advance, there is hope. November 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2024 Eight areas where gene therapy shines Delve into the numerous applications of gene therapy, from cancer to hematological disorders and respiratory diseases. November 21, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials. November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Nov 2024 Six bispecific antibody companies you should know about Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients. November 19, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Nov 2024 What is Abcam’s founder, Jonathan Milner, up to? Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy. November 18, 2024 - 17 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Nov 2024 How biotech startups become unicorns Delve into what differentiates a successful biotech startup from a unicorn reaching a $1 billion valuation. November 15, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 15 Nov 2024Beyond profits: The Bill & Melinda Gates MRI’s mission to combat neglected diseases This week, our guest is Dr Claire Wagner, head of corporate strategy and market access at the Bill & Melinda Gates Medical Research Institute (Gates MRI). November 15, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 14 Nov 2024 8 biotech companies advancing new treatments for breast cancer in 2024 Delve into the diverse landscape of breast cancer treatment with nine biotech companies currently developing new treatments. November 14, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 13 Nov 2024 Sleep apnea: biotechs snore points in the therapeutic space Therapeutic strides in biotech are proving to help address different stages of the sleep apnea. November 13, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2024 Six exosome therapy companies driving development in the field Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases. November 12, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email